BioLineRx Reports First Quarter 2020 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to BioLineRx Reports First Quarter 2020 Financial Results and Provides Corporate Update

BioLineRx (BLRX) Tops Q1 EPS by 62c

May 20, 2020 7:06 AM EDT

BioLineRx (NASDAQ: BLRX) reported Q1 EPS of ($0.04), $0.62 better than the analyst estimate of ($0.66).

Highlights and achievements during the first quarter 2020 and subsequent period:

Completed recruitment of the triple combination arm of the COMBAT/KEYNOTE-202 study;Continued to advance the COMBAT/KEYNOTE-202 study toward progression free survival (PFS) and overall survival (OS) data in mid-2020;Received Orphan Drug Designation for motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe;Announced Notice of Allowance from USPTO for a broad patent covering motixafortide in combination with... More